<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908319</url>
  </required_header>
  <id_info>
    <org_study_id>5122</org_study_id>
    <nct_id>NCT04908319</nct_id>
  </id_info>
  <brief_title>Hepatic Histopathology in Urea Cycle Disorders</brief_title>
  <official_title>Hepatic Histopathology in Urea Cycle Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, retrospective chart review as well as a prospective study to evaluate&#xD;
      histopathologic findings in liver samples from individuals with any UCD diagnosis. This study&#xD;
      will be conducted at all Urea Cycle Disorders Consortium (UCDC) sites: Baylor College of&#xD;
      Medicine in Houston, TX and Children's National Medical Center in Washington D.C.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With&#xD;
      early diagnosis and improved treatments, the survival of individuals with UCDs has improved,&#xD;
      and this improved survival has led to unmasking of some long-term complications such as&#xD;
      hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications&#xD;
      in UCDs are quite variable and dependent upon the specific metabolic defect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fibrosis</measure>
    <time_frame>Day 1</time_frame>
    <description>Staging of fibrosis from histopathology report from the liver biopsy or explant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steatosis</measure>
    <time_frame>Day 1</time_frame>
    <description>Grade of steatosis from histopathology report from the liver biopsy or explant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic glycogenosis</measure>
    <time_frame>Day 1</time_frame>
    <description>Presence and type of glycogenosis from histopathology report from the liver biopsy or explant</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Urea Cycle Disorder</condition>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <condition>Citrullinemia 1</condition>
  <condition>ARGI Deficiency</condition>
  <condition>ASL Deficiency</condition>
  <condition>Argininosuccinic Aciduria</condition>
  <condition>ASS Deficiency</condition>
  <condition>Hyperargininemia</condition>
  <condition>Carbamyl Phosphate Synthetase Deficiency</condition>
  <condition>NAGS Deficiency</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen liver samples, liver histology blocks/slides&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with urea cycle disorders&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary urea cycle disorder based on clinical suspicion confirmed by&#xD;
             enzyme activity, DNA testing or metabolite analysis.&#xD;
&#xD;
          -  History of liver transplantation and/or liver biopsy OR&#xD;
&#xD;
          -  Planned liver transplantation and/or liver biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unavailability of histopathology report from the liver biopsy or explant, or&#xD;
             unavailability of liver tissue or slides from the biopsy or explant OR&#xD;
&#xD;
          -  Anticipated inability to obtain pathology report, liver disease, tissue blocks, or&#xD;
             pathology slides after liver biopsy or transplantation&#xD;
&#xD;
          -  Known history of a secondary cause for liver disease such as chronic viral hepatitis,&#xD;
             autoimmune liver disease, short gut, small bowel syndrome, alcohol liver disease, or&#xD;
             TPN-related cholestatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Burrage, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saima Ali, MSN</last_name>
    <phone>832-822-4183</phone>
    <email>saima.ali@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Lindsay Burrage</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Liver transplant</keyword>
  <keyword>Liver disease</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Histopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
    <mesh_term>Citrullinemia</mesh_term>
    <mesh_term>Argininosuccinic Aciduria</mesh_term>
    <mesh_term>Hyperargininemia</mesh_term>
    <mesh_term>Carbamoyl-Phosphate Synthase I Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

